UBITUS
15.5.2024 11:34:35 CEST | Business Wire | Press release
Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.
Innovative Demonstrations at the Ubitus Booth
Ubitus is excited to showcase its AI technologies that increase creativity and productivity for everyone, including the debut of Ubi-chan in French and UbiArt, its visual art AI generative tool. Ubi-chan, Ubitus' AI V-tuber, will engage with attendees, providing an interactive experience that highlights the capabilities of AI in entertainment. Additionally, Ubitus will unveil UbiArt at the event, featuring unique “local style models” like the Taiwan Night Market, demonstrating the versatile applications of its technology in creating culturally rich digital art.
Keynote Speeches by CEO Wesley Kuo
Cloud vs Console: The Future of Gaming Platforms
Highlighting Ubitus' involvement, CEO Wesley Kuo will take the stage as an official speaker at VivaTech. Wesley Kuo is scheduled to present on "Cloud vs Console: The Future of Gaming Platforms" on May 23, from 9:45 AM to 10:30 AM on Stage 2. His speech session with Michael Fan, partner of Galaxy Interactive, and Joe Tidy, Cyber Correspondent of BBC News will address crucial topics in the gaming industry, discussing the transformative potential of cloud technology over traditional console platforms, impacts on market dynamics, the benefits of subscription-based models, and the implications for data privacy and game diversity. For more details on the session, please visit: https://vivatechnology.com/sessions/4a3a33b1-f2f0-ee11-aaf0-000d3a2b945f.
Introduction to Ubitus' AI Solutions
In addition, Wesley Kuo will deliver a second presentation on the main stage in the TTA Pavilion(Booth D38) at 2 PM on the same day, focusing on Ubitus' AI-driven initiatives.
Ubitus' participation in VivaTech 2024 showcases its commitment to innovation and its role in shaping the future of digital entertainment and AI applications. By introducing AI solutions like Ubi-chan, who will engage visitors in French, and UbiArt, which captures the essence of local cultures, showcasing the vibrant Taiwanese food culture, Ubitus is set to make a significant impact at this global tech event.
Join us at Viva Technology 2024 to experience the future of technology with Ubitus' innovative solutions. We look forward to welcoming you to our booth and sharing our vision for a connected world. For more information, please visit Ubitus K.K. website.
About Ubitus K.K.
Ubitus K.K. is a technology company that specializes in cloud solutions, GPU virtualization technology, and cloud streaming platform. Our focus is on delivering exceptional cloud and artificial intelligence services.
Leveraging the power of GPUs, Ubitus has developed multiple AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI character), and UbiArt (image generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Our goal is to seamlessly incorporate a range of AI applications into distinctive situations, ensuring a customized approach for each use case.
Ubitus’ cloud gaming solution enables users to enjoy AAA gaming experiences across devices with just an internet connection. Through our comprehensive Game Development Kit (GDK), we offer patented technology for rapid deployment, catering towards international clients that are interested in cloud gaming, including console gaming platforms, telecom operators, and game developers.
For Metaverse solutions, Ubitus possesses extensive global cloud deployment experience via GameCloud® technology offerings. Ubitus is able to stream interactive media content for platform operators and digital content developers on multi-devices, which offers users an immersive experience that accelerates metaverse popularization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515534843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom